5MZ3
P38 ALPHA MUTANT C162S IN COMPLEX WITH CMPD2 [N-(4-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide]
Summary for 5MZ3
Entry DOI | 10.2210/pdb5mz3/pdb |
Descriptor | Mitogen-activated protein kinase 14, ~{N}-[3-(2-acetamidoimidazo[1,2-a]pyridin-6-yl)-4-methyl-phenyl]-3-(trifluoromethyl)benzamide (3 entities in total) |
Functional Keywords | kinase, inhibitor, phosphotransferase, transferase |
Biological source | Homo sapiens (Human) |
Total number of polymer chains | 1 |
Total formula weight | 42897.79 |
Authors | Cowan-Jacob, S.W.,Scheufler, C. (deposition date: 2017-01-30, release date: 2017-11-15, Last modification date: 2018-11-07) |
Primary citation | Smith, A.,Ni, Z.J.,Poon, D.,Huang, Z.,Chen, Z.,Zhang, Q.,Tandeske, L.,Merritt, H.,Shoemaker, K.,Chan, J.,Kaufman, S.,Huh, K.,Murray, J.,Appleton, B.A.,Cowan-Jacob, S.W.,Scheufler, C.,Kanazawa, T.,Jansen, J.M.,Stuart, D.,Shafer, C.M. Imidazo[1,2-a]pyridin-6-yl-benzamide analogs as potent RAF inhibitors. Bioorg. Med. Chem. Lett., 27:5221-5224, 2017 Cited by PubMed: 29107542DOI: 10.1016/j.bmcl.2017.10.047 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.15 Å) |
Structure validation
Download full validation report